A panel of advisers to the Food and Drug Administration voted unanimously to recommend approval of an investigational gene therapy from Bluebird Bio on Friday, a one-time treatment that could be a cure for some patients with a rare blood disorder.
The group of independent experts voted 13-0 that the benefits of Bluebird’s gene therapy outweigh its risks for patients with beta-thalassemia, a disease that leads to severe anemia and requires patients to undergo frequent blood transfusions. The FDA is not required to follow the recommendations of its advisers, though it typically does. The agency has promised to render a final decision on Bluebird’s gene therapy, called beti-cel, by Aug. 19.
Continue to STAT+ to read the full story…
Click this link for the original source of this article.
Author: Damian Garde
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
